Results 41 to 50 of about 6,936,275 (299)
Functional consequences of the binding of MHC class ll-derived peptides to MHC class II [PDF]
Three MHC class II-derived synthetic peptides (I-A beta (g7)1-16, I-A beta (g7)52-77 and I-A alpha (g7)63-82YC) were analyzed for their ability to bind to syngeneic and allogeneic MHC class II molecules using a whole cell, competitive peptide binding assay.
Maryam Feili-Hariri +4 more
openaire +2 more sources
A peptide filtering relation quantifies MHC class I peptide optimization [PDF]
Major Histocompatibility Complex (MHC) class I molecules enable cytotoxic T lymphocytes to destroy virus-infected or cancerous cells, thereby preventing disease progression. MHC class I molecules provide a snapshot of the contents of a cell by binding to
Luca Cardelli +25 more
core +1 more source
A Hrd way for MHC-II expression
Major histocompatibility complex class II molecules (MHC-II), which present exogenous antigens to CD4+ T-lymphocytes, play an essential role in the initiation of the antigen-specific immune response. MHC-II is expressed in antigen presenting cells (APCs) including B cells, monocytes, macrophages and dendritic cells (DCs).
Johanna, Melo-Cardenas +2 more
openaire +2 more sources
Murine cytomegalovirus degrades MHC class II to colonize the salivary glands.
Cytomegaloviruses (CMVs) persistently and systemically infect the myeloid cells of immunocompetent hosts. Persistence implies immune evasion, and CMVs evade CD8+ T cells by inhibiting MHC class I-restricted antigen presentation.
Joseph Yunis +7 more
doaj +1 more source
Invariant Chain Complexes and Clusters as Platforms for MIF Signaling
Invariant chain (Ii/CD74) has been identified as a surface receptor for migration inhibitory factor (MIF). Most cells that express Ii also synthesize major histocompatibility complex class II (MHC II) molecules, which depend on Ii as a chaperone and a ...
Robert Lindner
doaj +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Background Based on binding of invariant chain (Ii) to major histocompatibility complex (MHC) class II molecules to form complexes, Ii-segment hybrids, Ii-key structure linking an epitope, or Ii class II-associated invariant chain peptide (CLIP) replaced
Chen Fangfang +5 more
doaj +1 more source
Bovine T cells recognize antigen in association with MHC class II haplotypes defined by one-dimensional isoelectric focusing [PDF]
A recently established, one-dimensional isoelectric focusing (IEF) method for distinguishing major histocompatibility complex (MHC) class II polymorphisms in an outbred species, cattle, has allowed us to analyse the involvement of the MHC in the ...
GLASS, EJ, OLIVER, RA, SPOONER, RL
core
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim +7 more
wiley +1 more source

